Improving survival in end-stage renal disease: A case study

Abstract

Background: With the increase of life expectancy,

*On behalf of the REIN registry.

end-stage renal disease (ESRD) is affecting a growing number of people. Simultaneously, renal replacement therapies (RRTs) have considerably improved patient survival. We investigated the way current RRT practices would affect patients' survival.

Methods: We used a multi-state model to represent the transitions between RRTs and the transition to death. The concept of “crude probability of death” combined with this model allowed estimating the proportions of ESRD-related and ESRD-unrelated deaths. Estimating the ESRD-related death rate requires comparing the mortality rate between ESRD patients and the general population. Predicting patients' courses through RRTs and Death states could be obtained by solving a system of Kolmogorov differential equations. The impact of practice on patient survival was quantified using the restricted mean survival time (RMST) which was compared with that of healthy subjects with same characteristics.

Results: The crude probability of ESRD-unrelated death was nearly zero in the youngest patients (18–45 years) but was a sizeable part of deaths in the oldest (≥70 years). Moreover, in the oldest patients, the proportion of expected death was higher in patient without vs. with diabetes because the former live older. In men aged 75 years at first RRT, the predicted RMSTs in patients with and without diabetes were, respectively, 61% and 69% those of comparable healthy men.

Conclusion: Using the concept of “crude probability of death” with multi-state models is feasible and useful to assess the relative benefits of various treatments in ESRD and help patient long-term management.

Keywords

End-stage renal disease multi-state models crude probability excess death restricted mean survival time

Get full access to this article

View all access options for this article.

References

Moeller

Gioberge

Brown

. ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 2002; 17: 2071–2076.

Parmar

. Chronic renal disease. BMJ 2002; 325: 85–90.

Shoji

Emoto

Shinohara

, et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117–2124.

Nesrallah

Mendelssohn

. Modality options for renal replacement therapy: the integrated care concept revisited. Hemodial Int 2006; 10: 143–151.

Wolfe

Ashby

Milford

, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730.

Ojo

Hanson

Meier-Kriesche

, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol 2001; 12: 589–597.

Rapport Annuel 2014 Réseau Epidémiologie et Information en Néphrologie. Registre Français des Traitements de Suppléance de l'Insuffisance Rénale Chronique, www.agence-biomedecine.fr/IMG/pdf/rapportrein2014.pdf (accessed 25 May 2017).

Couchoud

Stengel

Landais

, et al. The renal epidemiology and information network (REIN): a new registry for end-stage renal disease in France. Nephrol Dial Transplant 2006; 21: 411–418.

Lambert

Dickman

Nelson

, et al. Estimating the crude probability of death due to cancer and other causes using relative survival models. Stat Med 2010; 29: 885–895.

10.

Charvat

Bossard

Daubisse

, et al. Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancers. Cancer Epidemiol 2013; 37: 857–863.

11.

Smith Sehdev

Hutchins

. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med 2001; 161: 277–284.

12.

Yin

Morris

Bates

, et al. Effect of misclassified underlying cause of death on survival estimates of colon and rectal cancer. J Natl Cancer Inst 2011; 103: 1130–1133.

13.

Hinchliffe

Abrams

Lambert

. The impact of under and over-recording of cancer on death certificates in a competing risks analysis: a simulation study. Cancer Epidemiol 2013; 37: 11–19.

14.

Estève

Benhamou

Croasdale

, et al. Relative survival and the estimation of net survival: elements for further discussion. Stat Med 1990; 9: 529–538.

15.

Remontet

Estève

Bouvier

, et al. Cancer incidence and mortality in France over the period 1978–2000. Rev Epidemiol Sante Publique 2003; 51(1 Pt 1): 3–30.

16.

Andersen

Keiding

. Multi-state models for event history analysis. Stat Methods Med Res 2002; 11: 97–115.

17.

Couchoud

Dantony

Elsensohn

, et al. Modelling treatment trajectories to optimize the organization of renal replacement therapy and public health decision-making. Nephrol Dial Transplant 2013; 28: 2372–2382.

18.

Commenges

. Multi-state models in epidemiology. Lifetime Data Anal 1999; 5: 315–327.

19.

Hougaard

. Multi-state models: a review. Lifetime Data Anal 1999; 5: 239–264.

20.

Meira-Machado

de Uña-Alvarez

Cadarso-Suárez

, et al. Multi-state models for the analysis of time-to-event data. Stat Methods Med Res 2009; 18: 195–222.

21.

Schaubel

Morrison

Fenton

SSA

. Projecting renal replacement therapy-specific end-stage renal disease prevalence using registry data. Kidney Int 2000; 57(Suppl. 74): S49–S54.

22.

Remontet

Bossard

Belot

Estève

the French network of cancer registries FRANCIM . An overall strategy based on regression models to estimate survival and model the effects of prognostic factors in cancer survival studies. Stat Med 2007; 26: 2214–2228.

23.

Danieli

Remontet

Bossard

, et al. Estimating net survival: the importance of allowing for informative censoring. Stat Med 2012; 31: 775–786.

24.

Kay

. A Markov model for analysing cancer markers and disease states in survival studies. Biometrics 1986; 42: 855–865.

25.

Dantony

Elsensohn

Dany

, et al. Estimating the parameters of multi-state models with time-dependent covariates through likelihood decomposition. Comput Biol Med 2016; 69: 37–43.

26.

Beyersmann

Shumacher

Allignol

. Competing risks and multistate models with R, New York, NY: Springer, 2012.

27.

Andersen

Borgan

Gill

, et al. Statistical models based on counting processes, New York, NY: Springer, 1993.

28.

Blaizot

Riche

Maman

, et al. Estimation and short-term prediction of the course of the HIV epidemic using demographic and health survey methodology-like data. PLoS One 2015; 10: e0130387.

29.

Hoogenveen

van Baal

Boshuizen

. Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. Math Med Biol 2010; 27: 1–19.

30.

Cutler

Ederer

. Maximum utilization of the life table method in analyzing survival. J Chronic Dis 1958; 8: 699–712.

31.

Fink

Brown

. Survival analysis. Gastroenterol Hepatol 2006; 2: 380–383.

32.

Couchoud

Dantony

Elsensohn

, et al. Restricted mean survival time over 15 years for patients starting renal replacement therapy. Nephrol Dial Transplant 2017; 32(Suppl_2): ii60–ii67.

33.

Zhao

Claggett

Tian

, et al. On the restricted mean survival time curve in survival analysis. Biometrics 2016; 72: 215–221.

34.

Belot

Remontet

Launoy

, et al. Competing risk models to estimate the excess mortality and the first recurrent-event hazards. BMC Med Res Methodol 2011; 11: 78.

35.

Gilard-Pioc

Abrahamowicz

Mahboubi

, et al. Multi-state relative survival modelling of colorectal cancer progression and mortality. Cancer Epidemiol 2015; 39: 447–455.

36.

Gillaizeau

Dantan

Giral

, et al. A multistate additive relative survival semi-Markov model. Stat Methods Med Res 2017; 26: 1700–1711.

37.

Huszti

Abrahamowicz

Alioum

, et al. Relative survival multistate Markov model. Stat Med 2011; 31: 269–286.

38.

Meier P, Saudan P, Burnier M, et al. Comorbidité et facteurs de risque cardiovasculaire liés à l'insuffisance rénale chronique. Rev Med Suisse 2003; 1: 22862.

39.

Sud

Naimark

. Cardiovascular disease in chronic kidney disease in 2015. Curr Opin Nephrol Hypertens 2016; 25: 203–207.

40.

Franczyk

Gluba-Brzózka

Ciałkowska-Rysz

, et al. The problem of atrial fibrillation in patients with chronic kidney disease. Curr Vasc Pharmacol 2016; 14: 260–265.

41.

Couser

Remuzzi

Mendis

, et al. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80: 1258–1270.

42.

Fried

Katz

Sarnak

, et al. Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 2005; 16: 3728–3735.

43.

Tonelli

Wiebe

Culleton

, et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006; 17: 2034–2047.

44.

Marks

Macleod

McAteer

, et al. Chronic kidney disease, a useful trigger for proactive primary care? Mortality results from a large U.K. cohort. Fam Pract 2013; 30: 282–289.

45.

Thompson

James

Wiebe

, et al. Cause of death in patients with reduced kidney function. J Am Soc Nephrol 2015; 26: 2504–2511.

46.

James

Quan

Tonelli

, et al. CKD and risk of hospitalization and death with pneumonia. Am J Kidney Dis 2009; 54: 24–32.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.09 MB